Shares of uniQure NV (NASDAQ:QURE) rose 3.3% during mid-day trading on Friday . The company traded as high as $7.66 and last traded at $7.59, with a volume of 186,997 shares trading hands. The stock had previously closed at $7.35.

QURE has been the subject of a number of research reports. Chardan Capital reiterated a “buy” rating and issued a $40.00 price target on shares of uniQure NV in a report on Wednesday, March 23rd. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of uniQure NV in a report on Thursday, March 24th. Piper Jaffray Cos. restated an “overweight” rating and set a $26.00 target price on shares of uniQure NV in a report on Tuesday, April 5th. Oppenheimer Holdings Inc. restated a “buy” rating and set a $23.00 target price (down previously from $50.00) on shares of uniQure NV in a report on Tuesday, April 5th. Finally, Jefferies Group restated a “buy” rating on shares of uniQure NV in a report on Wednesday, April 6th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. uniQure NV currently has an average rating of “Buy” and an average price target of $30.80.

The stock’s 50-day moving average is $9.63 and its 200-day moving average is $13.04. The stock’s market cap is $189.12 million.

uniQure NV (NASDAQ:QURE) last posted its earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.10. On average, analysts predict that uniQure NV will post ($3.14) earnings per share for the current year.

An institutional investor recently raised its position in uniQure NV stock. Columbus Circle Investors increased its stake in shares of uniQure NV (NASDAQ:QURE) by 493.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 113,548 shares of the company’s stock after buying an additional 94,422 shares during the period. Columbus Circle Investors owned 0.47% of uniQure NV worth $1,878,000 at the end of the most recent quarter.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.